medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2017, Number 4

<< Back Next >>

Neumol Cir Torax 2017; 76 (4)

Ambulatory treatment of dyspnea with tunnelized indwelling pleural catheter in malignant pleural effusions. A descriptive study

Páez-Codeso FM, Dorado-Galindo A, Jiménez-Fernández DM, Bermejo-Casero E, Ruarte-Naranjo C, González-Angulo GE, Gutiérrez-Castaño P

Language: Spanish
References: 20
Page: 308-314
PDF size: 223.93 Kb.


Text Extraction

Objective: Describe the results of a consecutive group of patients treated with tunnelized indwelling pleural catheter (TIPC) (PleurX™) for dyspnea caused by malignant pleural effusion (MPE) until their death. Method: We included patients admitted for dyspnea caused by malignant pleural effusion from January to December 2016. We describe the insertion technique and analyse the patients’ origin, type of tumour, characteristics of the pleural effusion, complications, the quality of life and survival once the TIPC is inserted. Results: Accrued 21 patients, 11 men and 10 women, average age of 70 years (44-94). Primary histology: bronchogenic carcinoma 8 patients (38%), the rest being extrapulmonary carcinoma. Dyspnea improved in 15 patients (71%), by the mMRC scale. There were no re-admisions for dyspnea and/pleural effusions. Survived for an averge of 47 days (3-174). Complications: 3/21 cases (14%). The family members quickly learned the home drainage procedure, which did not overwork the caregiver. Conclusions: TIPC prevented readmission due to symptomatic pleural effusion. Symptoms of dyspnea and quality of life improved in majority of patients. The procedure has proven safe, effective with a few minor complications.


REFERENCES

  1. Beyea A, Winzelberg G, Stafford RE. To drain o not to drain: an evidence-based approach to palliative procedures for the management of malignant pleural effusions. J Pain Symptom Manage 2012;44(2):301-306. doi: 10.1016/j.jpainsymman.2012.05.002.

  2. Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med 2009;15(4):380-387 doi: 10.1097/MCP.0b013e32832c6a8a.

  3. Murthy SC, Rice TW. Surgical management of malignant pleural effusions. Thorac Surg Clin 2013;23(1):43-49. vi. doi: 10.1016/j.thorsurg.2012.10.001.

  4. Villena V, López-Encuentra A, Echave-Sustaeta J, Álvarez Martínez C, Martín Escribano P. Estudio prospectivo de 1000 pacientes consecutivos con derrame pleural. Etiología del derrame y características de los pacientes. Arch Bronconeumol 2002;38(1):21-26.

  5. Porcel JM, Esquerda A, Vives M, Bielsa S. Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas. Arch Bronconeumol 2014;50(5):161–165. doi: 10.1016/j.arbres.2013.11.007.

  6. Cano HM, Priede DL, Carrascosa PM. Tratamiento ambulatorio del derrame pleural maligno: aportación de un caso. Med Paliat 2012;19(1):3-9.

  7. Seijó L, Capo A, Alcaide AB, Lacunza MM, Armendáriz AC, Zulueta JJ. Manejo ambulatorio del derrame pleural maligno mediante colocación de un catéter pleural tunelizado. Experiencia preliminar. Arch Bronconeumol 2006;42(12):660-662.

  8. Musani AI, Haas AR, Seijo L, Wilby M, Sterman DH. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration 2004;71(6):559-566.

  9. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheters and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999;86(10):1992-1999.

  10. Brooks SM. Task group on surveillance for respiratory hazards in the occupational setting. Surveillance for respiratory hazards. American Thoracic Society News 1982;8:12-16.

  11. Cases E, Seijo L, Disdier C, et al. Uso del drenaje pleural permanente en el manejo ambulatorio del derrame pleural maligno recidivante. Arch Bronconeumol 2009;45(12):591-596. doi: 10.1016/j.arbres.2009.09.009.

  12. Zeldin DC, Rodríguez RM. Management of refractory malignant pleural effusions with chronic indwelling pleural catheter. Chest 1991;100:87S.

  13. Marín PJF, Moreno VMA, Soriano MM, et al. Suspensión de talco para efusión pleural maligna. Farmacia Hosp (Madrid) 2001;25(4):224-228.

  14. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004;(1):CD002916.

  15. Rivas de Andrés JJ. Pleurodesis: indicaciones, técnicas y resultados. Arch Bronconeumol 1984;6:56-62.

  16. Light RW. Talc should not be used for pleurodesis. Am J Respir Crit Care Med 2000;162(6):2024-2026.

  17. Sahn SA. Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000;162(6):2023-2024.

  18. Meier M, Mortensen MR, Larsen LU. Implantation of permanent pleural catheter for palliation of malignant pleural effusion. Cancer Manag Res 2016;8:129-133.

  19. Kaifi JT, Toth JW, Gusani NJ, et al. Multidisciplinary management of malignant pleural effusion. J Surg Oncol 2012;105(7):731-738. doi: 10.1002/jso.22100.

  20. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter. insertions for malignant pleural effusion. Chest 2006;129(2):362-368.




2020     |     www.medigraphic.com